SHARE CAPITAL |
|
a) |
Authorized share capital |
The Company is authorized to issue
an unlimited number of Class A Shares. The Class A Shares do not have any special rights or restrictions attached., respectively. The
Class A shares were converted to common shares on December 22, 2023, and as of December 31, 2023, there were 0 Class A Shares issued and
outstanding.
During the year ended December 31, 2023, the Company:
| i) | Issued 156,250 shares at a price of $14.40 per share for total proceeds of $2,250,000 in a registered direct offering. In connection with the offering, the Company incurred $226,544 in issuance costs as part of the transaction. |
| ii) | Issued 283,875 common shares pursuant to exercise of 283,875 warrants at a price of $17.37 per share for total proceeds of $4,561,200. |
| iii) | Issued 815,217 shares at a price of $3.68 per share for total proceeds of $3,000,000 in a registered direct offering. In connection with the offering, the Company incurred $453,345 in issuance costs as part of the transaction. |
| iv) | Issued 989,903 shares at a price of $2.59 per share for total proceeds of $2,562,660 in a private placement. |
| v) | Issued 21 shares upon the conversion of Class A shares. |
The Company may grant incentive stock
options to its officers, directors, employees, and consultants. The Company has implemented a rolling Stock Option Plan (the “Plan”)
whereby the Company can issue up to 10% of the issued and outstanding common shares of the Company. Options have a maximum term of ten
years and vesting is determined by the Board of Directors.
A continuity schedule of outstanding stock options is as
follows:
|
|
Number Outstanding |
|
|
Weighted Average Exercise Price |
|
|
|
|
|
|
($) |
|
Balance – December 31, 2022 |
|
|
14,238 |
|
|
|
594.08 |
|
Granted |
|
|
25,000 |
|
|
|
14.40 |
|
Exercised |
|
|
- |
|
|
|
- |
|
Forfeited |
|
|
(10,247 |
) |
|
|
392.60 |
|
Balance – December 31, 2023 |
|
|
28,990 |
|
|
|
165.38 |
|
Granted |
|
|
- |
|
|
|
- |
|
Exercised |
|
|
- |
|
|
|
- |
|
Forfeited |
|
|
(10,481 |
) |
|
|
150.48 |
|
Balance – March 31, 2024 |
|
|
18,509 |
|
|
|
173.81 |
|
During the periods ended March 31, 2024 and 2023 the Company recorded
share-based compensation of $160,865 and $1,247,113, respectively, relating to options vested during the period.
The Company used the following assumptions in calculating
the fair value of stock options for the period ended:
|
|
March 31, 2024 |
|
|
March 31, 2023 |
|
Risk-free interest rate |
|
|
3.93 |
% |
|
|
3.93 |
% |
Expected life of options |
|
|
3.38 years |
|
|
|
5.0 years |
|
Expected dividend yield |
|
|
Nil |
|
|
|
Nil |
|
Volatility |
|
|
132.65 |
% |
|
|
132.65 |
% |
At March 31, 2024, the Company had
incentive stock options outstanding as follows:
Expiry Date |
|
Options Outstanding
|
|
|
Exercise Price
|
|
|
Weighted Average Remaining Life |
|
|
|
|
|
|
($) |
|
|
(years) |
|
April 2, 2024 |
|
|
423 |
|
|
|
604.80 |
|
|
|
0.01 |
|
June 27, 2024 |
|
|
26 |
|
|
|
614.40 |
|
|
|
0.24 |
|
September 27, 2024 |
|
|
780 |
|
|
|
1,087.20 |
|
|
|
0.49 |
|
October 22, 2024 |
|
|
26 |
|
|
|
967.20 |
|
|
|
0.56 |
|
July 24, 2025 |
|
|
382 |
|
|
|
715.20 |
|
|
|
1.32 |
|
July 31, 2025 |
|
|
384 |
|
|
|
715.20 |
|
|
|
1.33 |
|
August 10, 2025 |
|
|
52 |
|
|
|
715.20 |
|
|
|
1.36 |
|
June 1, 2026 |
|
|
59 |
|
|
|
1,689.60 |
|
|
|
2.17 |
|
June 29, 2026 |
|
|
25 |
|
|
|
1,356.00 |
|
|
|
2.25 |
|
August 19, 2026 |
|
|
949 |
|
|
|
1,008.00 |
|
|
|
2.39 |
|
August 17, 2027 |
|
|
2,076 |
|
|
|
96.00 |
|
|
|
3.38 |
|
September 20, 2027 |
|
|
140 |
|
|
|
55.20 |
|
|
|
3.47 |
|
February 13, 2028 |
|
|
13,187 |
|
|
|
14.40 |
|
|
|
3.87 |
|
|
|
|
18,509 |
|
|
|
173.81 |
|
|
|
3.38 |
|
|
d) |
Share purchase warrants |
A continuity schedule of outstanding share purchase warrants
is as follows:
|
|
Number Outstanding |
|
|
Weighted Average Exercise Price |
|
|
|
|
|
|
($) |
|
Balance – December 31, 2022 |
|
|
329,908 |
|
|
|
91.84 |
|
Exercised |
|
|
(283,875 |
) |
|
|
16.19 |
|
Expired |
|
|
- |
|
|
|
- |
|
Issued |
|
|
850,612 |
|
|
|
3.83 |
|
Balance – December 31, 2023 |
|
|
896,645 |
|
|
|
32.36 |
|
Exercised |
|
|
- |
|
|
|
- |
|
Expired |
|
|
- |
|
|
|
- |
|
Issued |
|
|
- |
|
|
|
- |
|
Balance – March 31, 2024(1) |
|
|
896,645 |
|
|
|
32.36 |
|
|
(1) |
Unit A warrant balance is
7,030 as of March 31, 2024. |
During the year ended December 31, 2023, the Company:
| i) | Issued 10,938 placement agent warrants in conjunction with a registered direct offering on February 2, 2023, with an exercise price of $14.40 per share.
|
| ii) | Issued 815,217 warrants in conjunction with a public offering on October 17, 2023, with an exercise price of $3.68 per share. |
| iii) | Issued 24,457 placement agent warrants in conjunction with a public offering on October 17, 2023, with an exercise price of $4.05 per share. |
The Company used the following assumptions
in calculating the fair value of the warrants for the period ended:
|
|
March 31, 2024 |
|
|
December 31, 2023 |
|
Risk-free interest rate |
|
|
4.13% - 4.49% |
|
|
|
4.13% - 4.49% |
|
Expected life of warrants |
|
|
1.81 – 4.55 years |
|
|
|
2.06 – 4.80 years |
|
Expected dividend yield |
|
|
Nil |
|
|
|
Nil |
|
Volatility |
|
|
132.78% |
|
|
|
132.78% |
|
Weighted average fair value per warrant |
|
$ |
4.44 |
|
|
$ |
4.69 |
|
At March 31, 2024, the Company had
share purchase warrants outstanding as follows:
Expiration Date |
|
Warrants Outstanding
|
|
|
Exercise Price
|
|
|
Weighted Average
Remaining Life |
|
|
|
|
|
|
($) |
|
|
(years) |
|
January 20, 2026(1) |
|
|
7,030 |
|
|
|
1,800.00 |
|
|
|
1.81 |
|
February 28, 2027 |
|
|
20,689 |
|
|
|
460.80 |
|
|
|
2.92 |
|
December 6, 2027 |
|
|
13,781 |
|
|
|
20.00 |
|
|
|
3.68 |
|
December 9, 2027 |
|
|
9,876 |
|
|
|
17.60 |
|
|
|
3.69 |
|
January 18, 2028 |
|
|
25,906 |
|
|
|
124.80 |
|
|
|
3.80 |
|
February 2, 2028 |
|
|
10,938 |
|
|
|
14.40 |
|
|
|
3.85 |
|
October 17, 2028 |
|
|
783,968 |
|
|
|
3.68 |
|
|
|
4.55 |
|
October 17, 2028 |
|
|
24,457 |
|
|
|
4.05 |
|
|
|
4.55 |
|
|
|
|
896,645 |
|
|
|
32.36 |
|
|
|
4.44 |
|
(1) | Unit A warrant balance is 7,030 as of March 31, 2024. |
|